Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of $0.03, $0.16 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $4.95 million.

Earnings